Dr Abramson
Abramson J et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by ASCT as second-line treatment in patients with R/R large B-cell lymphoma: 3-year follow-up of TRANSFORM. EHA 2024;Abstract S272.
Bishop MR et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med 2022;386(7):629-39. Abstract
Chavez JC et al. 3-year analysis of ZUMA-12: A phase 2 study of axicabtagene ciloleucel (Axi-Cel) as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL). ASH 2023;Abstract 894.
Frank MJ et al. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: A dose-finding phase 1 study. Lancet 2024;404(10450):353-63. Abstract
Ghobadi A et al. Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7. Blood Adv 2024;8(11):2982-90. Abstract
Kramer AM et al. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: Continued durable remissions at 3-year follow-up. ASH 2024;Abstract 69.
Locke FL et al. Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL). ASCO 2023;Abstract 2517.
Locke FL et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386:640-54. Abstract
Neelapu SS et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 2023;141(19):2307-15. Abstract
Neelapu SS et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med 2022;28(4):735-42. Abstract
Riedell PA et al. Rapcabtagene autoleucel (YTB323) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): Phase II trial clinical update. ASH 2024;Abstract 67.
Shah NN et al. Interim results from a phase 2 pivotal study (DALY II USA) of tandem CD20-CD19-directed non-cryopreserved CAR-T cells - Zamtocabtagene autoleucel (Zamto-Cel) in patients with relapsed/refractory diffuse large B cell lymphoma. ASH 2024;Abstract 68.
Svoboda J et al. Safety and efficacy of armored huCART19-IL18 in patients with relapsed/refractory lymphomas that progressed after anti-CD19 CAR T cells. ASCO 2024;Abstract 7004.
Westin JR et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med 2023;389(2):148-57. Abstract
Prof Hutchings
Abramson J et al. Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Results of a global randomized phase III trial (STARGLO). EHA 2024;Abstract LB3438.
Crochet G et al. Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma. Blood 2024;144(3):334-8. Abstract
Dickinson MJ et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2022;387(24):2220-31. Abstract
Dickinson MJ et al. Phase I study of YTB323, a chimeric antigen receptor (CAR)-T cell therapy manufactured using T-Charge™, in patients with relapsed/refractory diffuse large B-cell lymphoma. EHA 2022;Abstract S212.
Hutchings M et al. Glofitamab plus polatuzumab vedotin continues to demonstrate frequent and durable responses and has a manageable safety profile in patients with ≥2L relapsed/refractory DLBCL, including HGBCL, and in patients with prior CAR T-cell therapy: Updated results from a phase Ib/II study. ASH 2023;Abstract 4460.
Jurczak W et al. Longer follow-up from the pivotal EPCORE NHL-1 trial reaffirms subcutaneous epcoritamab induces deep, durable complete remissions in patients with relapsed/refractory large B-cell lymphoma. EHA 2023;Abstract P1118.
Karimi Y et al. Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial. ASCO 2023;Abstract 7525.
Poon M et al. Odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL): Results from a prespecified analysis of the pivotal phase II study ELM-2. ICML 2023;Abstract 93.
Thieblemont C et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I/II trial. J Clin Oncol 2023;41(12):2238-47. Abstract
Thieblemont C et al. Subcutaneous epcoritamab induces deep, durable complete remissions in relapsed/refractory large B-cell lymphoma: Longer follow-up from the pivotal EPCORE NHL-1 trial. ICML 2023;Abstract 94.
Dr Lunning
Dreyling M et al. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update. Blood 2024;143(17):1713-25. Abstract
Ghione P et al. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Blood 2022;140(8):851-60. Abstract
Jacobson CA et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial. Lancet Oncol 2022;23(1):91-103. Abstract
Landsburg DJ et al. Efficacy and safety of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma: A real-world analysis from the center for blood and marrow transplant research (CIBMTR) registry. ASH 2024;Abstract 4398.
Morschhauser F et al. Lisocabtagene maraleucel in follicular lymphoma: The phase 2 TRANSCEND FL study. Nat Med 2024;30(8):2199-207. Abstract
Nastoupil L et al. Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Transcend FL 2-year follow-up. ASH 2024;Abstract 4387.
Neelapu SS et al. 5-year follow-up analysis from ZUMA-5: A phase 2 trial of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory indolent non-hodgkin lymphoma. ASH 2024;Abstract 864.
Neelapu SS et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood 2024;143(6):496-506. Abstract
Palomba ML et al. Lisocabtagene maraleucel (liso-cel) in patients (pt) with R/R MCL: Subgroup analyses in pts with high-risk disease features from the MCL cohort of the TRANSCEND NHL 001. ASTCT 2024;Abstract 17.
Salles G et al. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. Blood Adv 2022;6(22):5835-43. Abstract
van Meerten T et al. Primary analysis of ZUMA-2 cohort 3: Brexucabtagene autoleucel (brexu-cel) in patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) who were naive to Bruton tyrosine kinase inhibitors (BTKi). ASH 2024;Abstract 748.
Wang M et al. Five-year outcomes of patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-2 cohorts 1 and 2. ASH 2024;Abstract 4388.
Wang M et al. Lisocabtagene maraleucel in relapsed/refractory mantle cell lymphoma: Primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study. J Clin Oncol 2024;42(10):1146-57. Abstract
Wang M et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2020;382(14):1331-42. Abstract
Dr Phillips
Falchi L et al. Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial. ASCO 2022;Abstract 7524.
Kim TM et al. Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma. Ann Oncol 2024;35(11):1039-47. Abstract
Kim W-S et al. Odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Results from a prespecified analysis of the pivotal phase II study ELM-2. ASH 2022;Abstract 949.
Lori LA et al. Epcoritamab with rituximab + lenalidomide (R2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7. ASCO 2024;Abstract 7014.
Morschhauser F et al. Preliminary findings of a phase Ib/II trial indicate manageable safety and promising efficacy for mosunetuzumab in combination with lenalidomide (m+len) in previously untreated (1L) follicular lymphoma (FL). ASH 2023;Abstract 605.
Phillips TJ et al. Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study. ASCO 2024;Abstract 7008.
Schuster SJ et al. Mosunetuzumab monotherapy continues to demonstrate durable responses in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal phase II study. ASH 2023;Abstract 603.
Vose J et al. EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL. ASCO 2024;Abstract 7015.
Wang ML et al. Fixed duration mosunetuzumab plus polatuzumab vedotin has promising efficacy and a manageable safety profile in patients with BTKi relapsed/refractory mantle cell lymphoma: Initial results from a phase Ib/II study. ASH 2023;Abstract 734.
Dr Crombie
Chakrabordy R et al. Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies. Transplant Cell Ther 2021;27(3):222-9. Abstract
Crombie JL et al. Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Blood 2024;143(16):1565-75. Abstract
Fowler NH et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial. Nat Med 2022;28(2):325-32. Abstract
Hamilton MP et al. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N Engl J Med 2024;390(22):2047-60. Abstract
Jacobson CA et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial. Lancet Oncol 2022;23(1):91-103. Abstract
Kamdar M et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): Results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 2022;399(10343):2294-308. Abstract
Ozdemirli M et al. Indolent CD4+ CAR T-cell lymphoma after cilta-cel CAR T-cell therapy. N Engl J Med 2024;390(22):2074-82. Abstract
Rejeski K et al. CAR-HEMATOTOX: A model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood 2021;138(24):2499-513. Abstract
Santomasso B et al. The other side of CAR T-cell therapy: Cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book 2019;39:433-44. Abstract